Skip to main content
NCBI home page
Journal of Neurology, Neurosurgery, and Psychiatry logoLink to Journal of Neurology, Neurosurgery, and Psychiatry
. 1983 Dec;46(12):1146–1148. doi: 10.1136/jnnp.46.12.1146

Failure of a peripheral dopaminergic marker in Parkinson's disease.

J M Maloteaux, C E Laterre, L Hens, P M Laduron
PMCID: PMC491783  PMID: 6663315

Abstract

[3H]-spiperone binding on human lymphocytes did not reveal the occurrence of dopamine receptors. However, lower values were observed in Parkinsonism and the displaceable binding was increased after levodopa treatment although this was not specific only for levodopa and, furthermore, was not correlated with the clinical symptomatology. This non-specific binding in lymphocytes corresponds to trapping, presumably in lysosomes and thus does not reflect the dopaminergic receptors state in Parkinson's disease.

Full text

PDF
1146

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Brodde O. E. Demonstration of vascular dopamine receptors in membranes from rabbit renal artery using 3H-spiroperidol binding. Experientia. 1981 Oct 15;37(10):1099–1101. doi: 10.1007/BF02085035. [DOI] [PubMed] [Google Scholar]
  2. Brosnan C. F., Bunge M. B., Murray M. R. The response of lysosomes in cultured neurons to chlorpromazine. J Neuropathol Exp Neurol. 1970 Jul;29(3):337–353. doi: 10.1097/00005072-197007000-00001. [DOI] [PubMed] [Google Scholar]
  3. Fleminger S., Jenner P., Marsden C. D. Are dopamine receptors present on human lymphocytes? J Pharm Pharmacol. 1982 Oct;34(10):658–663. doi: 10.1111/j.2042-7158.1982.tb04696.x. [DOI] [PubMed] [Google Scholar]
  4. Le Fur G., Meininger V., Baulac M., Phan T., Uzan A. Récepteurs dopaminergiques lymphocytaires et maladie de Parkinson idiopathique. Rev Neurol (Paris) 1981;137(2):89–96. [PubMed] [Google Scholar]
  5. Le Fur G., Meininger V., Phan T., Gérard A., Baulac M., Uzan A. Decrease in lymphocyte [3H]spiroperidol binding sites in Parkinsonism. Life Sci. 1980 Oct 27;27(17):1587–1591. doi: 10.1016/0024-3205(80)90568-8. [DOI] [PubMed] [Google Scholar]
  6. Lee T., Seeman P., Rajput A., Farley I. J., Hornykiewicz O. Receptor basis for dopaminergic supersensitivity in Parkinson's disease. Nature. 1978 May 4;273(5657):59–61. doi: 10.1038/273059a0. [DOI] [PubMed] [Google Scholar]
  7. Leysen J. E., Gommeren W., Laduron P. M. Spiperone: a ligand of choice for neuroleptic receptors. 1. Kinetics and characteristics of in vitro binding. Biochem Pharmacol. 1978 Feb 1;27(3):307–316. doi: 10.1016/0006-2952(78)90233-2. [DOI] [PubMed] [Google Scholar]
  8. Magistretti P. J., Schorderet M. Dopamine receptors in bovine retina : characterization of the 3H-spiroperidol binding and its use for screening dopamine receptor affinity of drugs. Life Sci. 1979 Nov 5;25(19):1675–1686. doi: 10.1016/0024-3205(79)90409-0. [DOI] [PubMed] [Google Scholar]
  9. Maloteaux J. M., Waterkein C., Laduron P. M. Absence of dopamine and muscarinic receptors on human lymphocytes. Arch Int Pharmacodyn Ther. 1982 Jul;258(1):174–176. [PubMed] [Google Scholar]
  10. Seeman P., Chau-Wong M., Tedesco J., Wong K. Brain receptors for antipsychotic drugs and dopamine: direct binding assays. Proc Natl Acad Sci U S A. 1975 Nov;72(11):4376–4380. doi: 10.1073/pnas.72.11.4376. [DOI] [PMC free article] [PubMed] [Google Scholar]
  11. de Duve C., de Barsy T., Poole B., Trouet A., Tulkens P., Van Hoof F. Commentary. Lysosomotropic agents. Biochem Pharmacol. 1974 Sep 15;23(18):2495–2531. doi: 10.1016/0006-2952(74)90174-9. [DOI] [PubMed] [Google Scholar]

Articles from Journal of Neurology, Neurosurgery, and Psychiatry are provided here courtesy of BMJ Publishing Group

RESOURCES